Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting
03 Novembro 2023 - 1:00PM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) products for cancer, today presented preclinical
data on a novel off-the-shelf AlloCAR T product candidate targeting
Claudin18.2 (CLDN18.2)-positive gastric and pancreatic tumors, at
the Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 1-5, 2023, in San Diego, CA.
Data presented at SITC describes preclinical development of
Allogene’s novel allogeneic CLDN18.2 CAR T product candidate with
the potential to provide clinical benefit to patients with a
single, off-the-shelf infusion. CLDN18.2 has emerged as a promising
therapeutic target, with high expression in many types of
epithelial tumors including gastric, esophageal, pancreatic and
ovarian cancers.
“Proof of concept for a CAR T targeting Claudin18.2 has been
established, but limitations of autologous therapies, including the
need for leukapheresis, long manufacturing wait times in patients
with recent chemotherapy exposure, and high tumor and comorbidity
burdens, would likely restrict availability to patients,” said
Zachary Roberts, M.D., Ph.D., Executive Vice President of Research
& Development and Chief Medical Officer of Allogene. “An
allogeneic product, derived from healthy donors and readily
available to patients at the time of progression has the potential
to overcome such challenges. We believe these preclinical data
support a pathway to targeting CLDN18.2-positive solid tumors with
an AlloCAR T product. This preclinical research further elucidates
the depth of opportunity for our solid tumor program, and the
potential to bring one of the most exciting modalities in modern
times to patients in need.”
The preclinical evaluation identified candidates with potent
activity in both short-term and repeat stimulation in vitro
cytotoxicity assays. The lead IND candidates researched displayed
robust antitumor activity at low cell doses in vivo against both
subcutaneous and intraperitoneal gastric cancer models. Data
suggest the existence of a therapeutic window and the potential to
target CLDN18.2 with allogeneic off-the-shelf CAR T cells without
significant off tumor toxicity. These data were the foundation for
ALLO-182, currently in the IND-enabling phase of development.
ALLO-182 together with ALLO-213, an allogeneic CAR T targeting
DLL3, represent the company’s early-stage solid tumor product
candidates.
About Allogene TherapeuticsAllogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the development of
allogeneic chimeric antigen receptor T cell (AlloCAR T™) products
for cancer. Led by a management team with significant experience in
cell therapy, Allogene is developing a pipeline of “off-the-shelf”
CAR T product candidates with the goal of delivering readily
available cell therapy on-demand, more reliably, and at greater
scale to more patients. For more information, please visit
www.allogene.com, and follow @AllogeneTx on X (formerly Twitter)
and LinkedIn.
Cautionary Note on Forward-Looking Statements for
AllogeneThis press release contains forward-looking
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. The press release
may, in some cases, use terms such as “advance,” "predicts,"
"believes," “suggests,” "potential," "proposed," "continue,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things
Allogene’s ability to develop and deliver readily available
allogeneic CAR T products for cancer treatment on-demand, more
reliably, and at greater scale to more patients. Various factors
may cause material differences between Allogene’s expectations and
actual results, including risks and uncertainties related to: our
product candidates are based on novel technologies, which makes it
difficult to predict the time and cost of product candidate
development and obtaining regulatory approval; the extent to which
the FDA disagrees with our clinical or regulatory plans,
which could cause delays to our IND approval and future clinical
trials or require additional clinical trials; and we may not be
able to demonstrate the safety and efficacy of our product
candidates in our clinical trials, which could prevent or delay
regulatory approval and commercialization. These and other risks
are discussed in greater detail in Allogene’s filings with
the SEC, including without limitation under the “Risk Factor”
Heading in its Form 10-Q filed for the quarter ended September
30, 2023. Any forward-looking statements that are made in this
press release speak only as of the date of this press release.
Allogene assumes no obligation to update the forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene’s AlloCAR T™ programs utilize Cellectis technologies.
The Claudin18.2 AlloCAR T program is licensed exclusively from
Cellectis by Allogene and Allogene holds global development and
commercial rights to this AlloCAR T program.
Allogene Media/Investor Contact:Christine
CassianoChief Corporate Affairs & Brand Strategy
OfficerChristine.Cassiano@allogene.com
Additional Allogene Media Contacts:Leslie
BryantLeslie.Bryant@allogene.com
Madeleine GoldsteinMadeleine.Goldstein@allogene.com
Allogene Therapeutics (NASDAQ:ALLO)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Allogene Therapeutics (NASDAQ:ALLO)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024